Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.
Saved in:
| Title: | Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma. |
|---|---|
| Authors: | Harvey MJ; Analysis Group, Inc., London, United Kingdom., Zhong Y; Analysis Group, Inc., Menlo Park, California, United States of America., Morris E; Analysis Group, Inc., Menlo Park, California, United States of America., Beverage JN; Halozyme Therapeutics, San Diego, California, United States of America., Epstein RS; Epstein Health, LLC, Woodcliff Lake, New Jersey, United States of America., Chawla AJ; Analysis Group, Inc., Menlo Park, California, United States of America. |
| Source: | PloS one [PLoS One] 2022 Jan 24; Vol. 17 (1), pp. e0261336. Date of Electronic Publication: 2022 Jan 24 (Print Publication: 2022). |
| Publication Type: | Comparative Study; Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0261336 |
